Allogene Therapeutics Inc...
(ALLO)
undefined
undefined%
At close: undefined
1.94
2.92%
After-hours Dec 13, 2024, 06:59 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue,
expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | 95.00K | 243.00K | 38.49M | - | - | - | - |
| Cost of Revenue | 242.91M | 16.73M | 13.06M | 11.54M | 5.03M | 1.50M | - |
| Gross Profit | -242.82M | -16.48M | 25.42M | -11.54M | -5.03M | -1.50M | - |
| Operating Income | -327.74M | -335.45M | -255.79M | -258.24M | -202.01M | -192.84M | -2.00K |
| Interest Income | 18.31M | 4.57M | 1.71M | 9.16M | 17.35M | 5.79M | - |
| Pretax Income | -327.26M | -332.63M | -257.00M | -250.22M | -184.93M | -211.62M | -2.00K |
| Net Income | -327.26M | -329.81M | -244.84M | -233.47M | -184.59M | -211.50M | -2.00K |
| Selling & General & Admin | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 2.00K |
| Research & Development | 242.91M | 256.39M | 220.18M | 192.99M | 144.53M | 151.86M | - |
| Other Expenses | 13.24M | -1.75M | -2.93M | -1.14M | -268.00K | -21.21M | - |
| Operating Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Interest Expense | - | - | - | - | - | 3.36M | - |
| Selling & Marketing Expenses | - | - | - | - | - | - | -22.00K |
| Cost & Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Income Tax | - | -2.82M | -12.17M | -16.75M | -331.00K | -117.00K | -24.00K |
| Shares Outstanding (Basic) | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
| Shares Outstanding (Diluted) | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
| EPS (Basic) | -2.09 | -2.3 | -1.8 | -1.94 | -1.83 | -7.31 | - |
| EPS (Diluted) | -2.09 | -2.3 | -1.8 | -1.94 | -1.83 | -7.31 | - |
| EBITDA | -300.29M | -321.24M | -169.74M | -250.81M | -179.90M | -206.76M | 22.00K |
| Depreciation & Amortization | 14.20M | 14.29M | 10.45M | 11.54M | 5.03M | 1.50M | 24.00K |